Document Detail


How modeling and simulation have enhanced decision making in new drug development.
MedLine Citation:
PMID:  16283534     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug development and development decision-making. Examples are presented that support this paradigm. The first example describes a preclinical model of behavioral activity to predict potency and time-course of response in humans and assess the potential for differentiation between compounds. This example illustrates how modeling procedures expounded by Lewis Sheiner provided the means to differentiate potency and the lag time between drug exposure and response and allow for rapid decision making and dose selection. The second example involves planning a Phase 2a dose-ranging and proof of concept trial in Alzheimer's disease (AD). The issue was how to proceed with the study and what criteria to use for a go/no go decision. The combined knowledge of AD disease progression, and preclinical and clinical information about the drug were used to simulate various clinical trial scenarios to identify an efficient and effective Phase 2 study. A design was selected and carried out resulting in a number of important learning experiences as well as extensive financial savings. The motivation for this case in point was the "Learn-Confirm" paradigm described by Lewis Sheiner. The final example describes the use of Pharmacokinetic and Pharmacodynamic (PK/PD) modeling and simulation to confirm efficacy across doses. In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia. The clinical trial data was not replicated for each of the sought dose levels in the drug application presenting a regulatory dilemma. Exposure response analysis submitted in the New Drug Application was applied to confirm the evidence of efficacy across these dose levels. Modeling and simulation analyses showed that the two studies corroborate each other with respect to the pain relief profiles. The use of PK/PD information confirmed evidence of efficacy across the three studied doses, eliminating the need for additional clinical trials and thus supporting the approval of the product. It can be speculated that the work by Lewis Sheiner reflected in the FDA document titled "Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products" made this scientific approach to the drug approval process possible.
Authors:
Raymond Miller; Wayne Ewy; Brian W Corrigan; Daniele Ouellet; David Hermann; Kenneth G Kowalski; Peter Lockwood; Jeffrey R Koup; Sean Donevan; Ayman El-Kattan; Cheryl S W Li; John L Werth; Douglas E Feltner; Richard L Lalonde
Related Documents :
23628584 - Chitosan coated alginate/poly(n-isopropylacrylamide) beads for dual responsive drug del...
2143234 - Pharmacologically guided phase i clinical trials based upon preclinical drug development.
20426354 - Fever management: evaluating the use of ibuprofen and paracetamol.
18828764 - What's next in the pipeline.
8527834 - Update on computer-aided drug design.
3327674 - Aspects on the benefit-risk balance of felodipine in hypertension.
Publication Detail:
Type:  Journal Article; Review     Date:  2005-11-07
Journal Detail:
Title:  Journal of pharmacokinetics and pharmacodynamics     Volume:  32     ISSN:  1567-567X     ISO Abbreviation:  J Pharmacokinet Pharmacodyn     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-11-25     Completed Date:  2006-02-15     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  101096520     Medline TA:  J Pharmacokinet Pharmacodyn     Country:  England    
Other Details:
Languages:  eng     Pagination:  185-97     Citation Subset:  IM    
Affiliation:
Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA. raymond.miller@pfizer.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / drug therapy
Amines / pharmacology
Animals
Clinical Trials, Phase II as Topic / statistics & numerical data
Clinical Trials, Phase III as Topic / statistics & numerical data
Computer Simulation*
Cyclohexanecarboxylic Acids / pharmacology
Decision Making, Computer-Assisted*
Excitatory Amino Acid Antagonists / pharmacology
Herpesviridae Infections / complications
Humans
Models, Statistical*
Neuralgia / drug therapy,  etiology
Pharmacology / statistics & numerical data*
Software
gamma-Aminobutyric Acid / pharmacology
Chemical
Reg. No./Substance:
0/Amines; 0/Cyclohexanecarboxylic Acids; 0/Excitatory Amino Acid Antagonists; 56-12-2/gamma-Aminobutyric Acid; 6CW7F3G59X/gabapentin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conditioning on certain random events associated with statistical variability in PK/PD.
Next Document:  Analyzing multi-response data using forcing functions.